Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 326 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 May 20, 2021 Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... January 5, 2023 Should People with Cancer and Cancer Survivors Get the Flu Vaccine? September 2, 2020 Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer June 7, 2019 Load more HOT NEWS ESMO Breast Cancer Virtual Congress 2021, 5-8 May Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms National Study Examines Genetic Testing to Inform Follow-up Care for Cancer... Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in...
